Soligenix Enhances Advisory Board to Advance HyBryte™ for CTCL Treatment Development

Soligenix Strengthens Medical Advisory Board to Propel HyBryte™ Development

Soligenix, Inc., a biopharmaceutical company dedicated to developing treatments for rare diseases, announces a strategic enhancement to its U.S. Medical Advisory Board (MAB). This development is pivotal for advancing HyBryte™ (synthetic hypericin), which targets cutaneous T-cell lymphoma (CTCL), a rare and challenging form of non-Hodgkin's lymphoma. The updated MAB now includes renowned dermatologic and oncologic experts who bring invaluable experience to the ongoing FLASH2 Phase 3 pivotal clinical trial. Their involvement is expected to significantly influence the clinical development path of HyBryte™, with a focus on addressing the specific needs of CTCL patients.

The newly appointed members of the MAB include key opinion leaders who have previously served as principal investigators in the HyBryte™ clinical program. Their intimate knowledge of the product and its developmental journey enhances the board's capability to provide strategic insights for Soligenix. The MAB will focus on various critical aspects such as clinical strategies, potential home-use applications of HyBryte™, and considerations for health economics and reimbursement. This multifaceted approach aims to ensure that HyBryte™ not only meets clinical efficacy standards but also aligns with the economic realities of treatment adoption in healthcare systems.

Dr. Christopher J. Schaber, President and CEO of Soligenix, expresses enthusiasm about the new additions, emphasizing their expertise and prior involvement with HyBryte™ as vital assets to the program’s success. This strategic move highlights Soligenix's commitment to addressing the unmet medical needs of patients suffering from rare diseases. By leveraging expert guidance, the company aims to optimize clinical outcomes while simultaneously facilitating the successful commercialization of HyBryte™ on a global scale.

In addition to the MAB enhancements, Soligenix continues to engage with global health authorities to ensure that regulatory pathways are navigated effectively. The expertise of the advisory board members will be instrumental in shaping interactions with these entities, contributing to a smoother development process for HyBryte™. This collaborative approach underscores the company's dedication to providing innovative solutions for patients facing rare diseases and reinforces its position as a leader in the biopharmaceutical sector.

As Soligenix moves forward with its development plans, the focus remains on ensuring that HyBryte™ meets the needs of CTCL patients, ultimately aiming to improve their quality of life. The strategic insights gained from the updated MAB will play a crucial role in guiding the company through the complexities of clinical development and commercialization, paving the way for potential breakthroughs in the treatment of rare diseases.